Alza finds more it likes at Alkermes

Alkermes Inc. and Alza Corp. were to announce today that they have agreed to develop and commercialize RMP-7, ALKS's permeation enhancing agent to deliver drugs across the blood-brain barrier.

The deal is the second this year between the two companies, and could bring AZA's total investment in its ALKS partnership to $110 million. In February, AZA gained a 9.7 percent interest in ALKS through the purchase of $50 million newly issued, unregistered shares of ALKS. Simultaneously, the companies agreed to develop and commercialize an undisclosed product using one of two of ALKS' drug delivery technologies, ProLease or Medisorb.

Under the new agreement, AZA (Palo Alto,

Read the full 1127 word article

How to gain access

Continue reading with a
two-week free trial.